Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety rounds as a tool to improve quality and safety in postoperative care units: A quasi-experimental study.

Revista espanola de anestesiologia y reanimacion·2026
Same author

Integrative metagenomic and metabolomic profiling identifies faecal biomarkers of prolonged social stress in pigs.

Animal : an international journal of animal bioscience·2026
Same author

Effect of space allowance and transport container height on the welfare of fattening rabbits under different environmental thermal conditions.

Frontiers in veterinary science·2025
Same author

Preserved ambulation in a puppy with severe thoracolumbar myelodysplasia.

The Journal of small animal practice·2025
Same author

Comparing right colon adenoma detection rate during water exchange and air insufflation: a double-blind randomized controlled trial.

Techniques in coloproctology·2021
Same author

Estimating personal solar ultraviolet radiation exposure through time spent outdoors, ambient levels and modelling approaches.

The British journal of dermatology·2021

Related Experiment Video

Updated: May 25, 2026

Ex Vivo Hepatic Perfusion Through the Portal Vein in Mouse
05:30

Ex Vivo Hepatic Perfusion Through the Portal Vein in Mouse

Published on: March 9, 2022

[Anesthesia in the patient with impaired liver function].

A Sabaté1, F Acosta Villegas, A Dalmau

  • 1Servicio de Anestesiología y Reanimación, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona. asabatep@bellvitgehospital.cat

Revista Espanola De Anestesiologia Y Reanimacion
|January 28, 2012
PubMed
Summary

This review covers impaired liver function in anesthesia and surgery, detailing complications and risks. Surgical decisions for liver cirrhosis patients depend on Child-Pugh class and MELD scores to minimize perioperative mortality.

More Related Videos

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Related Experiment Videos

Last Updated: May 25, 2026

Ex Vivo Hepatic Perfusion Through the Portal Vein in Mouse
05:30

Ex Vivo Hepatic Perfusion Through the Portal Vein in Mouse

Published on: March 9, 2022

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Area of Science:

  • Anesthesiology
  • Hepatology
  • Surgical Risk Assessment

Context:

  • Impaired liver function significantly impacts anesthetic management and postoperative recovery.
  • Liver cirrhosis presents complex challenges, including coagulation disorders and increased bleeding risks.
  • Surgical outcomes in patients with liver disease are closely linked to disease severity.

Purpose:

  • To review key concepts of impaired liver function relevant to anesthesia and surgical recovery.
  • To analyze systemic effects and surgical complications in patients with liver cirrhosis.
  • To discuss the controversial management of coagulation disorders in cirrhotic patients.

Summary:

  • Perioperative morbidity and mortality correlate with Child-Pugh class and Model for End-Stage Liver Disease (MELD) scores.
  • Patients in Child class A face moderate risk; elective surgery is generally feasible.
  • High-risk patients (Child class C or MELD > 20) should avoid elective procedures, especially abdominal surgery due to hepatic blood flow changes and portal hypertension.

Impact:

  • Provides guidance for risk stratification and surgical decision-making in patients with liver dysfunction.
  • Highlights the importance of considering liver disease severity (Child-Pugh, MELD) in perioperative care planning.
  • Informs anesthetic and surgical strategies to mitigate complications in cirrhotic patients.